Our Company was established in 1957 by top leading pharmacists in order to supply excipients, APIs and specialty chemicals to Turkish Pharma Industry. From the beginning, the company has been adopted to high-quality service generating solutions to customers and suppliers as a leader of sustainable relations.
Marmara Ecza is an official distributor of Evonik, Meggle, Blanver, Omya, IGH Flavours in Turkey and also, strategic supplier of Ashland, Roquette, Budenheim, Konya Þeker. Moreover, Marmara Ecza is supplying almost every raw materials which are used in pharmaceutical, cosmetic, OTC and veterinary medicine industries via their own certified warehouses in compliance with GDP standarts and logistics.
Contact
Marmara Ecza ve Kimyevi Maddeler Sanayi ve Ticaret A.S.
Ikitelli OSB Suleyman Demirel Bulvari Ziya Gokalp Mah. Sinpas Is Modern F Blok No:37 Basaksehir Istanbul
T: +90 (212) 520 54 35/36
F: +90 (212) 526 26 25
email: marmaraecza@marmaraecza.com.tr
Web: marmaraecza.com.tr
Tugce Gozacan (pictured) and Okan Gozacan, Owner and Chairman of Marmara Ecza respectively, discuss what qualities are crucial for suppliers in the pharmaceutical industry, their process for forming partnerships and…
A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in…
A roundup of the latest pharma and healthcare news from Turkey including Omya’s new Turkish manufacturing site, Santa Farma’s fourth EU-GMP certification and the collaboration agreement between BioNTech and Turkey’s…
A roundup of the latest pharma and healthcare news from Turkey including Roche Turkey’s digital platform for HCPs and patients, big pharma’s aid to earthquake victims, the Scientific and Technological…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
After its best financial year to date – posting revenues of USD 27.3 billion in 2021 – Gilead has said yes to localization in Turkey. The California-based company, known for…
Turkey’s pharma market, the 18th largest in the world and valued at USD 7 Billion in 2020, has seen steady growth over the past few years due to favorable healthcare…
With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological…
Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…
Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive…
When the Turkish Ministry of Health implemented its strategy to transition from import pharmaceuticals to manufacturing them at home in 2016, the local industry leveraged the situation to invest in…
As an upper-middle-income country with an emerging economy, Turkey could not invest billions in COVID-19 vaccine R&D, but a strong research ecosystem and willing industry allowed it to kickstart multiple…
Overseeing healthcare for a population of over 80 million, Turkey’s Ministry of Health was put under the spotlight during the COVID-19 pandemic. Here, we highlight four of the hot-button items…
See our Cookie Privacy Policy Here
